MedTrace Logo

Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia

NCT06468774 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2025-07-30

No results posted yet for this study

Summary

Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals.

This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals.

Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.

Conditions

  • Chronic Mesenteric Ischemia
  • Median Arcuate Ligament Syndrome
  • Crohn Disease
  • Cholelithiasis

Interventions

PROCEDURE

Laparoscopic surgery

The patients in the MALS group will be treated through transperitoneal ventral approach for the laparoscopic release of the celiac artery. Median arcuate ligament and any muscle or nerve tissue crossing the cranial surface of the celiac artery will be divided to release the celiac artery from compression. In the patients with CMI open antegrade or retrograde bypass to celiac artery or superior mesenteric artery or both will be performed. For operative treatment will be performed in general anaethesia whereas the endovacular treatment with PTA with stent for CMI will be performed in local anaethesia.

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Syed Sajid Hussain Kazmi, MD, PhD · Department of vascular surgery, Oslo University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2037-05-31
Completion
2037-05-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06468774 on ClinicalTrials.gov